证券代码：300937 证券简称：药易购 公告编号：2024-032 四川合纵药易购医药股份有限公司 关于签署《关于设立及收购目标公司之合作框架协议》的 进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 四川合纵药易购医药股份有限公司（以下简称"公司"）于 2021 年 10 月 17 日召开第二届董事会 2021 年第六次会议审议通过了《关于签署<关于设立及 收购目标公司之合作框架协议>的议案》，公司拟与自然人杨亚、曹继军（以下 统称"乙方"）围绕享健药易购健康科技有限公司（以下简称"目标公司"）进行股 权合作。乙方为广州逸生汇商贸有限公司（下称"逸生汇"）、广州沁威网络科技 有限公司（下称"沁威"）、广州市享健贸易有限公司（下称"享健"）实际控制人 及股东，逸生汇、沁威、享健主要从事健康产品的网络销售及信息服务等方面业 务。乙方同意设立目标公司，并由目标公司对逸生汇、享健和沁威三家公司进行 资产、业务及人员整合重组，公司有意向以现金方式购买目标公司全体股东所持 目标公司 51%的股权。具体内容详见公司在巨潮资讯网（www.cninfo.com.cn ...

四川合纵药易购医药股份有限公司（以下简称"公司"）于 2021 年 10 月 17 日召开第二届董事会 2021 年第六次会议审议通过了《关于签署<关于设立及 收购目标公司之合作框架协议>的议案》，公司拟与自然人杨亚、曹继军（以下 统称"乙方"）围绕享健药易购健康科技有限公司（以下简称"目标公司"）进行股 权合作。乙方为广州逸生汇商贸有限公司（下称"逸生汇"）、广州沁威网络科技 有限公司（下称"沁威"）、广州市享健贸易有限公司（下称"享健"）实际控制人 及股东，逸生汇、沁威、享健主要从事健康产品的网络销售及信息服务等方面业 务。乙方同意设立目标公司，并由目标公司对逸生汇、享健和沁威三家公司进行 资产、业务及人员整合重组，公司有意向以现金方式购买目标公司全体股东所持 目标公司 51%的股权。具体内容详见公司在巨潮资讯网（www.cninfo.com.cn） 披露的《关于签署<关于设立及收购目标公司之合作框架协议>的提示性公告》（公 告编号：2021-041）。 前期，目标公司已完成设立并取得了营业执照，公司已依约向共管账户支付 诚意金 5,000 万元，基于诚信原则并按照前期协议约定允许将诚意金用于商品采 购及 ...

证券代码：300937 证券简称：药易购 公告编号：2024-030 四川合纵药易购医药股份有限公司 2023年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 四川合纵药易购医药股份有限公司(以下简称"公司")2023 年年度权益分 派方案已获 2024 年 4 月 30 日召开的 2023 年度股东大会审议通过，具体详见公 司于 2024 年 4 月 30 日在巨潮资讯网（www.cninfo.com.cn）披露的《2023 年度 股东大会决议公告》。现将权益分派事宜公告如下： 一、股东大会审议通过的利润分配方案的情况 1、公司 2023 年度具体利润分配方案为：以目前总股本 95,666,682 股为基 数，每 10 股派发现金红利 2.20 元人民币（含税），共计派发现金股利人民币 21,046,670.04 元（含税），剩余未分配利润继续留存公司用于支持公司经营需 要，不送红股，不实施以资本公积金转增股本。如在利润分配预案披露至实施期 间，公司总股本发生变动的，公司拟维持每股分配比例不变的原则，相应调整分 配总数。 2、本次权益分 ...

公司以原告及目标公司为反诉被告向法院提出了反诉，诉讼请求为：（1） 判令解除反诉原告与反诉被告一杨亚、反诉被告二曹继军签订的《合作意向书》、 《关于设立及收购目标公司之合作框架协议》、《合作框架协议之补充协议》。 （2）判令反诉被告一、二立即为反诉被告三办理更名及工商变更登记手续，反 诉被告三不再使用"药易购"作为其企业名称组成部分。（3）判令三反诉被告 共同向反诉原告双倍返还诚意金 1 亿元，并自 2023 年 5 月 17 日起以 1 亿元为基 数，按全国银行间同业拆借中心公布的一年期贷款市场报价利率支付逾期付款利 息，直至三反诉被告全部付清之日止。（4）判令三反诉被告共同向反诉原告赔 偿审计费、评估费、公证费、律师费、差旅费等各项损失，并依法承担本案诉讼 费、保全费、担保费。 进展公告 证券代码：300937 证券简称：药易购 公告编号：2024-029 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 四川合纵药易购医药股份有限公司（以下简称"公司"）于 2021 年 10 月 17 日召开第二届董事会 2021 年第六次会议审议通过了《关于签署<关于设 ...

出席本次说明会的人员有：公司董事长李燕飞女士；副董事长、总经理陈顺 军先生；董事会秘书沈金洋先生；财务总监郑德强先生；保荐代表人罗泽先生； 独立董事邓博夫先生等。 为充分尊重投资者、提升交流的针对性，现就公司 2023 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可提前登录深 圳证券交易所"互动易"平台（http://irm.cninfo.com.cn）的"云访谈"栏目 进入公司本次业绩说明会页面进行提问。公司将在 2023 年度业绩说明会上，对 投资者普遍关注的问题进行回答。此次活动交流期间，投资者仍可登陆活动界面 进行互动提问。 欢迎广大投资者积极参与本次网上说明会！ 特此公告。 四川合纵药易购医药股份有限公司 证券代码：300937 证券简称：药易购 公告编号：2024-028 四川合纵药易购医药股份有限公司 关于举行 2023 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 四川合纵药易购医药股份有限公司（以下简称"公司"）《2023 年年度报告》 及摘要已于 2024 年 4 月 10 日在巨 ...

四川合纵药易购医药股份有限公司 关于公司2024年第一季度计提减值准备的公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 四川合纵药易购医药股份有限公司（以下简称"公司"或"本公司"）根据《深 圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》 《企业会计准则》以及公司相关会计政策的规定，计提了信用减值损失及资产 减值损失，现将本次计提减值准备的具体情况公告如下： 一、本次计提减值准备原因和情况概述 根据《企业会计准则》等相关规定的要求，为真实准确地反映公司截至 2024年3月31日的财务状况和经营成果，公司对截止2024年3月31日的应收账 款、应收票据、其他应收款、存货等各类资产进行了减值测试，对可能存在减 值迹象的资产计提减值准备。2024年1-3月，公司计提减值损失共计 16,419,174.30元，其中信用减值损失17,055,956.13元，资产减值损失-636,781.83 元。 股票代码：300937 股票简称：药易购 公告编号：2024-026 | 项目 | 2024年第一季度计提减值准备金额 （元） | | --- | - ...

Revenue and Profit - Revenue for the first quarter of 2024 was RMB 1,237,408,296.37, a 10.29% increase compared to the same period last year[5] - Total revenue for Q1 2024 reached 1,237,408,296.37 RMB, a 10.3% increase compared to 1,121,966,149.54 RMB in the same period last year[18] - Net profit attributable to shareholders of the listed company was RMB 9,225,531.31, a 70.84% decrease year-over-year[5] - Net profit attributable to the parent company was 9,225,531.31 RMB, a significant decline from 31,632,639.16 RMB in Q1 2023[20] - Operating profit declined sharply to 6,447,362.40 RMB, an 81.3% decrease from 34,406,195.40 RMB in Q1 2023[20] - Basic earnings per share decreased to 0.0964 RMB, down 70.8% from 0.3300 RMB in the same period last year[20] Cash Flow - Net cash flow from operating activities improved by 38.50% to RMB -72,039,212.99 compared to the same period last year[5] - Net cash flow from operating activities was -72.04 million yuan, an improvement from the previous period's -117.14 million yuan[22] - Net cash flow from investing activities was -9.34 million yuan, compared to -7.40 million yuan in the previous period[22] - Net cash flow from financing activities was 82.75 million yuan, a significant improvement from the previous period's -106.43 million yuan[22] - The net increase in cash and cash equivalents was 1.37 million yuan, compared to a decrease of 230.98 million yuan in the previous period[23] - The ending balance of cash and cash equivalents was 192.86 million yuan, up from 103.62 million yuan in the previous period[23] Assets and Liabilities - Total assets increased by 14.90% to RMB 1,938,430,288.21 compared to the end of the previous year[5] - Total assets increased to 1,938,430,288.21 RMB, up 14.9% from 1,687,065,227.46 RMB at the end of the previous quarter[17] - Total liabilities grew by 29.4% to 1,075,166,045.38 RMB compared to 831,023,467.80 RMB at the end of the previous quarter[17] - Total equity increased slightly to 863,264,242.83 RMB, up 0.8% from 856,041,759.66 RMB at the end of the previous quarter[18] - The company's monetary funds at the end of the period amounted to 378,472,730.05 yuan, an increase from 374,864,119.57 yuan at the beginning of the period[16] - Total current assets increased to 1,625,252,317.69 yuan from 1,376,442,625.78 yuan at the beginning of the period[16] - Long-term equity investments increased to 16,371,914.19 yuan from 10,829,001.79 yuan at the beginning of the period[16] - Fixed assets slightly decreased to 141,531,353.32 yuan from 142,203,630.71 yuan at the beginning of the period[16] - Construction in progress increased to 6,063,976.47 yuan from 2,205,713.34 yuan at the beginning of the period[16] - Intangible assets decreased to 45,423,955.95 yuan from 46,432,202.40 yuan at the beginning of the period[16] Accounts Receivable and Payable - Accounts receivable increased by 271.89% to RMB 457,924,110.30 due to sales growth and extended payment terms[9] - Accounts receivable increased significantly to 457,924,110.30 yuan from 123,134,181.47 yuan at the beginning of the period[16] - Accounts payable increased significantly by 68.7% to 356,872,520.01 RMB from 211,493,306.55 RMB in the previous quarter[17] Borrowings and Financial Expenses - Short-term borrowings increased by 27.43% to RMB 408,706,533.89 due to new working capital loans[9] - Short-term borrowings rose by 27.4% to 408,706,533.89 RMB compared to 320,738,176.85 RMB in the previous quarter[17] - Financial expenses surged by 86.50% to RMB 2,082,577.74 mainly due to increased interest expenses[9] - The company received 176 million yuan from borrowings, compared to 0 in the previous period[23] - The company repaid 88 million yuan of debt, a decrease from the previous period's 105.42 million yuan[23] Sales and R&D Expenses - Sales expenses increased by 22.78% to RMB 53,858,024.16 due to expanded sales scale and increased promotion costs[9] - R&D expenses increased slightly to 4,797,456.92 RMB, up 2.7% from 4,671,770.57 RMB in Q1 2023[18] - Sales of goods and services received cash of 977.65 million yuan, an increase of 26.25% compared to the previous period's 774.39 million yuan[22] Investment Activities - Investment activities cash outflow increased by 26.25% to RMB -9,344,760.89 due to new investments[10] - Net cash flow from investing activities was -9.34 million yuan, compared to -7.40 million yuan in the previous period[22] Shareholders and Ownership - The total number of ordinary shareholders at the end of the reporting period is 14,126[11] - Li Yanfei, the largest shareholder, holds 36.97% of the shares, totaling 35,370,000 shares[11] Inventory - Inventory decreased to 516,841,959.20 yuan from 561,237,355.76 yuan at the beginning of the period[16] Audit Status - The company's first quarter report was not audited[24]

证券代码：300937 证券简称：药易购 公告编号：2024-024 四川合纵药易购医药股份有限公司 关于签署《关于设立及收购目标公司之合作框架协议》的 公司于 2022 年 11 月 10 日收到广东省广州市黄埔区人民法院送达的《民事 起诉状》《应诉通知书》等法律文书，乙方杨亚、曹继军以公司为被告提起民事 诉讼，具体内容详见公司在巨潮资讯网（www.cninfo.com.cn）披露的《四川合 纵药易购医药股份有限公司关于公司收到民事起诉状的公告》（公告编号： 2022-072）。 广州市中级人民法院裁定本案由广东省广州市黄埔区人民法院审理。公司代 理律师收到原告向法院递交的《变更诉讼请求申请书》及《追加第三人申请书》， 原告申请将诉讼请求变更为：（1）判令解除原告与被告签订的《合作意向书》、 《关于设立及收购目标公司之合作框架协议》及其补充协议。（2）判令被告赔 偿原告各类损失合计人民币 79,294,293.84 元。（3）判令被告向原告返还目标公 司的设立及运营成本合计人民币 2,000 万元。（4）判令被告承担本案全部诉讼 费、保全费、财产保全担保费等费用；同时，申请追加目标公司为本案第三人。 公司以 ...

Financial Performance - The company's operating revenue for 2023 was approximately RMB 4.43 billion, representing an increase of 11.62% compared to RMB 3.97 billion in 2022[21]. - The net profit attributable to shareholders for 2023 was approximately RMB 59.53 million, a significant increase of 41.69% from RMB 42.02 million in 2022[21]. - The net profit after deducting non-recurring gains and losses was approximately RMB 54.03 million, up 37.40% from RMB 39.32 million in 2022[21]. - The total assets at the end of 2023 were approximately RMB 1.69 billion, reflecting a growth of 6.00% from RMB 1.59 billion at the end of 2022[21]. - The basic earnings per share for 2023 were RMB 0.62, an increase of 40.91% compared to RMB 0.44 in 2022[21]. - The cash flow from operating activities showed a net outflow of approximately RMB 115.47 million, a decline of 175.64% compared to a net inflow of RMB 152.67 million in 2022[21]. - The weighted average return on equity for 2023 was 7.16%, an increase of 1.87% from 5.29% in 2022[21]. - The company reported quarterly revenues of RMB 1.22 billion in Q4 2023, with a net profit of RMB 9.37 million for the same quarter[23]. - The company's revenue increased from CNY 3.969 billion in 2022 to CNY 4.430 billion in 2023, representing a year-on-year growth of 11.62%[80]. - The net profit attributable to shareholders reached CNY 59.53 million in 2023, a year-on-year increase of 41.69%[80]. - The company's terminal pure sales amounted to CNY 2.504 billion in 2023, reflecting a growth of 5.56% compared to the previous year[80]. Market Trends and Industry Insights - The total sales volume of China's pharmaceutical circulation market reached CNY 2,751.6 billion in 2022, with a year-on-year growth of 6.0%[31]. - The retail pharmaceutical market sales amounted to CNY 599.0 billion, reflecting a year-on-year increase of 10.7%[31]. - The wholesale pharmaceutical market sales were CNY 2,152.6 billion, with a year-on-year growth of 5.4%[31]. - The market share of public hospitals has decreased to 61.8%, while retail pharmacies have increased their market share to 29%[33]. - By 2029, the external market is expected to reach CNY 1.6 trillion, potentially surpassing the internal market[34]. - The implementation of the Marketing Authorization Holder (MAH) system has led to over 2,000 companies obtaining B-class drug production licenses, enhancing industry competition[35]. - New regulations for online drug sales are expected to promote the healthy development of the pharmaceutical e-commerce sector[36]. - The "Seven Unifications" policy is set to enhance the regional collaborative advantages of large-scale enterprises starting January 1, 2024[37]. - The online sales proportion in the pharmaceutical retail market reached 28.9% in 2022, up from 8.1% in 2017, indicating a significant shift towards digital channels[42]. - The outpatient market for prescription drugs in China is currently below 30%, indicating significant growth potential compared to over 70% in countries like the US and Japan[147]. Business Strategy and Operations - The company's main business includes a comprehensive pharmaceutical distribution service, focusing on the outpatient market, which aligns with the trend of shifting from hospital to outpatient markets[44]. - The company operates approximately 23,000 pharmaceutical products across various categories, including Western medicine, traditional Chinese medicine, and medical devices, to meet outpatient market demands[49]. - The company has established a SBBC (Suppliers to key Business partners to small Business partners to Customers) ecosystem, enhancing supply chain efficiency and reducing distribution costs[46]. - The company has 14 wholly-owned subsidiaries, 14 holding companies, and 15 joint-stock companies, indicating a robust corporate structure for expansion[48]. - The company aims to become a leader in the digital health ecosystem by leveraging innovative technologies and enhancing service capabilities[44]. - The implementation of outpatient management in retail pharmacies is expected to boost the outpatient market's growth potential significantly[40]. - The company has been recognized as a national-level e-commerce demonstration enterprise, reflecting its industry standing and commitment to innovation[44]. - The integration of digital technologies in the pharmaceutical supply chain is essential for enhancing service efficiency and establishing a new business model in the industry[39]. - The company has established a distribution system with over 3,500 lower-level distributors, enhancing its market reach[50]. - The company has built a logistics system with independent operations through its wholly-owned subsidiary, Yao Yida Logistics, to meet the increasing demand for timely delivery[58]. E-commerce and Digital Transformation - The company has successfully established an online retail team and store matrix, with significant growth in online retail business from its invested companies[61]. - The company has achieved 78,800 effective customers through its e-commerce platform by the end of 2023, representing a growth rate of 7.87% compared to 2022[65]. - The average weekly active users (stores) reached 15,500 in 2023, with a growth rate of 5.80% from the end of 2022[65]. - E-commerce business revenue for 2023 was reported at 1.707 billion yuan, with a slight decrease of 2.01% from 2022[72]. - The average transaction amount per order was 1,251.48 yuan in 2023, showing an increase of 5.83% compared to the previous year[65]. - The company has signed contracts with 52 suppliers for advertising services, generating a total of 1.2344 million yuan in revenue[66]. - The company has established a comprehensive pharmaceutical service ecosystem in the outpatient market, enhancing supply chain advantages and expanding product resources[74]. - The company has invested in smart warehousing and logistics, improving operational efficiency and reducing costs through modernized systems[75]. - The company has focused on integrating traditional pharmaceutical distribution with internet and big data technologies, significantly enhancing transaction efficiency[72]. - The company has developed a digital health ecosystem, integrating AI, big data, and internet solutions to enhance operational efficiency and support business strategies[60]. Research and Development - The company achieved a research and development investment of ¥33,218,791.22 in 2023, representing an increase from ¥17,707,719.44 in 2022[108]. - The R&D investment accounted for 0.75% of the company's operating revenue in 2023, up from 0.45% in 2021[108]. - The number of R&D personnel increased to 119 in 2023, a growth of 1.71% compared to 117 in 2022[108]. - The company has increased its focus on drug research and development, leveraging partnerships with large pharmaceutical research institutions[108]. - The proportion of capitalized R&D expenditures reached 42.31% of total R&D investment in 2023[108]. Governance and Management - The company has established a governance structure that complies with relevant laws and regulations, ensuring independent operations from its controlling shareholder[170]. - The board of directors consists of 8 members, including 3 independent directors, meeting legal requirements and ensuring effective governance[171]. - The company has implemented a fair and effective performance evaluation and incentive mechanism for senior management, combining base salary with annual performance assessments[175]. - The company maintains independence from its controlling shareholder in terms of assets, personnel, finance, and operations, with no violations reported regarding fund occupation or guarantees[177]. - The annual shareholders meeting held on May 11, 2023, had an investor participation rate of 63.72%[178]. - The first extraordinary shareholders meeting on September 13, 2023, recorded a participation rate of 56.84%[179]. - The company is currently led by a board of directors with a mix of experienced professionals, including a chairperson and several independent directors[181]. - The company has a total of 12 directors and supervisors, with varying levels of remuneration[196]. - The company has established a comprehensive remuneration policy based on operational goals and performance assessments[195]. Risks and Challenges - The company highlighted risks including intensified market competition, changes in market demand, and potential failures in new business expansions[3]. - The company is facing significant risks of failure or substantial initial losses in expanding new businesses, particularly in retail and C-end operations, due to pressures on talent, management capabilities, and long-term mechanisms[163]. - There are ongoing lawsuits related to contract disputes, with uncertain impacts on future profits, prompting the company to form a dedicated team to manage these legal issues[164]. - The company faces risks from intensified market competition and changing market demands, necessitating a focus on enhancing its strengths and expanding coverage in the out-of-hospital market[158]. - The implementation of the MAH system presents new opportunities for transformation in the pharmaceutical distribution sector, while also increasing regulatory pressures[160].

四川合纵药易购医药股份有限公司 信会师报字[2024]第ZD10066号 四川合纵药易购医药股份有限公司全体股东： 2023 年度募集资金存放与使用情况 专项报告的鉴证报告 2023 年度 关于四川合纵药易购医药股份有限公司 2023年度募集资金存放与使用情况 专项报告的鉴证报告 我们接受委托，对后附的四川合纵药易购医药股份有限公司（以 下简称"药易购"） 2023年度募集资金存放与使用情况专项报告（以 下简称"募集资金专项报告"）执行了合理保证的鉴证业务。 一、董事会的责任 （2022年修订）》（证监会公告〔2022〕15号）、《深圳证券交易所 上市公司自律监管指引第2号——创业板上市公司规范运作》以及《深 圳证券交易所创业板上市公司自律监管指南第2号——公告格式》的 相关规定编制，如实反映药易购2023年度募集资金存放与使用情况获 取合理保证。在执行鉴证工作过程中，我们实施了包括询问、检查会 计记录等我们认为必要的程序。我们相信，我们的鉴证工作为发表鉴 证结论提供了合理的基础。 药易购董事会的责任是按照中国证券监督管理委员会《上市公司 监管指引第2号——上市公司募集资金管理和使用的监管要求（2022 年修 ...